Merck announced on Thursday that its experimental combination therapy for certain adult HIV-1 patients has met the primary efficacy and safety goals of two late-stage studies. The company stated that compared to Gilead Sciences' three-in-one pill Biktarvy and various other antiretroviral therapies, Merck's Doravirine/Islatravir combination therapy is not inferior in suppressing viral replication. Merck plans to submit the data to regulatory agencies and present detailed study results at future medical meetings.